The authors report a case of deficiency of the eighth component of complement in a young adult with a history of three episodes of meningitis; one of them proved to be meningococcal. The literature ...

The New York Yankees are retaining a familiar infield option, agreeing to a one year deal with Amed Rosario, according to YES Network’s Jack Curry. The contract is valued at $2.5 million, with an ...

Social media platforms have become key venues for public discourse and opinion shaping in today’s digital age. Understanding this, our research focuses on the influential role of Facebook in shaping ...

Complement-depleted and -non-depleted BALB/c mice were inoculated with Leishmania (Leishmania) amazonensis promastigotes into the hind footpad to study the role of the complement system in cutaneous ...

Los Angeles Lakers guard Austin Reaves is having a career season, averaging 29.3 points per game and ranking fifth in the league in scoring this season. But fantastic as Reaves is playing this season ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

Investing.com -- Q32 Bio Inc (NASDAQ:QTTB) stock surged 94% in premarket trading Monday after the clinical-stage biotechnology company announced the sale of its Phase 2 complement inhibitor, ADX-097, ...

Investing.com -- Q32 Bio Inc (NASDAQ:QTTB) stock surged 94% in premarket trading Monday after the clinical-stage biotechnology company announced the sale of its Phase 2 complement inhibitor, ADX-097, ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

DelveInsight’s Geographic Atrophy Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging geographic atrophy drugs, market share of individual therapies, ...